Fmoc-Nva-OH | (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)pentanoic acid | Carbamates

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 135112-28-6 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 135112-28-6 ]

CAS No. :	135112-28-6
Formula :	C₂₀H₂₁NO₄
M.W :	339.39
SMILES Code :	CCC[C@@H](C(O)=O)NC(OCC1C2=CC=CC=C2C3=CC=CC=C13)=O
Synonyms :	(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)pentanoic acid
MDL No. :	MFCD00155631
InChI Key :	JBIJSEUVWWLFGV-SFHVURJKSA-N
Pubchem ID :	7016885

Safety of [ 135112-28-6 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 135112-28-6 ] Show Less

Physicochemical Properties

Num. heavy atoms	25
Num. arom. heavy atoms	12
Fraction Csp3	0.3
Num. rotatable bonds	8
Num. H-bond acceptors	4.0
Num. H-bond donors	2.0
Molar Refractivity	94.79
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	75.63 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.53
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.94
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.78
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.78
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.32
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	3.27

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-4.25
Solubility	0.0189 mg/ml ; 0.0000558 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-5.23
Solubility	0.00201 mg/ml ; 0.00000592 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-5.69
Solubility	0.000696 mg/ml ; 0.00000205 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	Yes
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	Yes
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.57 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.56

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<2.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	3.75

Application In Synthesis of [ 135112-28-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 135112-28-6 ]

[ 135112-28-6 ] Synthesis Path-Downstream 1~24

1
[ 98-00-0 ]
[ 135112-28-6 ]
[ 98-68-0 ]
[ 160885-98-3 ]
N-(2-furfuryl)-N-(4-methoxybenzenesulfonyl)-L-norvalinyl-L-valinol [ No CAS ]

References: [1]Journal of Organic Chemistry,2000,vol. 65,p. 5048 - 5056.

2
[ 636-72-6 ]
[ 135112-28-6 ]
[ 98-68-0 ]
[ 160885-98-3 ]
N-(2-thienylmethyl)-N-(4-methoxybenzenesulfonyl)-L-norvalinyl-L-valinol [ No CAS ]

References: [1]Journal of Organic Chemistry,2000,vol. 65,p. 5048 - 5056.

3
[ 624-95-3 ]
[ 135112-28-6 ]
[ 98-68-0 ]
[ 160885-98-3 ]
N-(3,3-dimethylbutyl)-N-(4-methoxybenzenesulfonyl)-L-norvalinyl-L-valinol [ No CAS ]

References: [1]Journal of Organic Chemistry,2000,vol. 65,p. 5048 - 5056.

4
[ 135112-28-6 ]
[ 98-68-0 ]
[ 160885-98-3 ]
[ 100-51-6 ]
N-benzyl-N-(4-methoxybenzenesulfonyl)-L-norvalinyl-L-valinol [ No CAS ]

References: [1]Journal of Organic Chemistry,2000,vol. 65,p. 5048 - 5056.

5
[ 7409-30-5 ]
[ 71989-35-0 ]
[ 135112-28-6 ]
[ 125238-99-5 ]
benzoic anhydride [ No CAS ]
Bz-Dab-Nva-Thr-NH-CH₂PhNO₂ [ No CAS ]

References: [1]Organic and Biomolecular Chemistry,2003,vol. 1,p. 93 - 99.

6
[ 71989-35-0 ]
[ 135112-28-6 ]
[ 125238-99-5 ]
3-allyloxycarbonylamino-benzoic acid [ No CAS ]
p-nitrobenzoic acid [ No CAS ]
Bz(NO₂)-Dab-Nva-Thr-(3-aminobenzoyl)-NH₂ [ No CAS ]

References: [1]Organic and Biomolecular Chemistry,2003,vol. 1,p. 93 - 99.

7
[ 135112-28-6 ]
[ 98-68-0 ]
[ 160885-98-3 ]
N-(4-methoxybenzenesulfonyl)-L-norvalinyl-L-valinol [ No CAS ]

References: [1]Journal of Organic Chemistry,2000,vol. 65,p. 5048 - 5056.

8
[ 71989-35-0 ]
[ 135112-28-6 ]
[ 125238-99-5 ]
3-allyloxycarbonylamino-benzoic acid [ No CAS ]
benzoic anhydride [ No CAS ]
p-nitrobenzylamine [ No CAS ]
Bz-Dab-Nva-Thr-(3-aminobenzoyl)-NHCH₂PhNO₂ [ No CAS ]

References: [1]Organic and Biomolecular Chemistry,2003,vol. 1,p. 93 - 99.

9
[ 71989-18-9 ]
[ 132684-59-4 ]
[ 77284-32-3 ]
[ 135112-28-6 ]
[ 125238-99-5 ]
N-(9-fluorenylmethoxycarbonyl)-3-(β-naphthyl)-L-alanine [ No CAS ]
[ 1349220-85-4 ]

References: [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 5229 - 5237.

10
[ 35661-39-3 ]
[ 71989-31-6 ]
[ 71989-33-8 ]
[ 35737-15-6 ]
[ 73724-45-5 ]
[ 71989-31-6 ]
[ 135112-28-6 ]
[ 132684-60-7 ]
[ 161420-87-7 ]
[ 158599-00-9 ]
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-fluorophenyl)propanoic acid [ No CAS ]
Fmoc-D-Dab(NH<SUB>2</SUB>)-OH [ No CAS ]
cyclo(-((S)-2-aminopentanoyl)-Ser-((S)-2-amino-3-(4-fluorophenyl)propanoyl)-((S)-2,4-diaminobutanoyl)-Orn-(D-2,4-diaminobutanoyl)-((S)-2,4-diaminobutanoyl)-Trp-((S)-2,4-diaminobutanoyl)-((S)-2-amino-3,3-dimethylbutanoyl)-Ala-Ser-(D-Pro)-Pro-) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: [0798] In a dried flask, 2-chlorotritylchloride resin (polystyrene, 1% crosslinked; loading: 1.4 mmol/g) was swollen in dry CH2C12 for 30 mm (7 ml CH2C12 per g resin). A solution of 0.8 eq of the Fmoc-protected amino acid and 6 eq of DIPEA in dry CH2C12/DMF (4/1) (10 ml per g resin) was added. Afier shaking for 2-4 h at it the resin was filtered off and washed successively with CH2C12, DMF, CH2C12, DMF and CH2C12. Then a solution of dry CH2C12/MeOH/DIPEA (17:2:1) was added (10 ml perg resin).Afier shaking for 3x30 mm the resin was filtered off in a pre-weighed sinter funnel and washed successively with CH2C12, DMF, CH2C12, MeOH, CH2C12, MeOH, CH2C12 (2x) and Et20 (2x). The resin was dried under high vacuum overnight. The final mass of resin was calculated before the qualitative control.[0803] After assembly of the linear peptide, the resin was suspended in 1 ml of 1% TFA in CH2C12 (v/v; 0.14 mmol) for 3 minutes and filtered, and the filtrate was neutralized with 1 ml of 20% DIPEA in CH2C12 (v/v; 1.15 mmol). This procedure was repeated four times to ensure completion of the cleavage. The resin was washed three times with 1 ml of CH2C12. The CH2C12 layers containing product were evaporated to dryness.10804] The fully protected linear peptide was solubilised in8 ml of dry DMF. Then 2 eq. of HA11J and 2. eq. of HOAt in dry DMF (1-2 ml) and 4 eq. of DIPEA in dry DMF (1-2 ml) were added to the peptide, followed by stirring for ca. 16 h. The volatiles were removed by evaporation. The crude cyclic peptide was dissolved in 7 ml of CH2C12 and washed three times with 4.5 ml 10% acetonitrile in water (v/v). The CH2C12 layer was then evaporated to dryness.10805] To fully deprotect the peptide, 7 ml of cleavage cocktail TFADODT/thioanisol/H20 (87.5:2.5:5:5) were added, and the mixture was kept for 2.5-4 hat room tempera- tare until the reaction was completed. The reaction mixture was evaporated close to dryness and the peptide precipitated with 7 ml of cold Et20. The precipitate was washed 3 times with 4 ml of cold Et20.

References: [1]Patent: US2016/52971,2016,A1 .Location in patent: Paragraph 0798-0805; 0834-0836.

11
[ 35661-39-3 ]
[ 35661-38-2 ]
[ 77284-32-3 ]
[ 71989-31-6 ]
[ 135112-28-6 ]
[ 143674-78-6 ]
[ 170642-27-0 ]
[ 112883-41-7 ]
C₆₂H₈₄N₉O₁₃Pol [ No CAS ]